XML 33 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash flows from operating activities    
Net loss $ (10,475,582) $ (12,600,007)
Adjustments to reconcile net loss to cash used in operating activities    
Depreciation, amortization and accretion 3,780,310 1,974,213
Stock-based compensation expense and restricted stock issuance 590,826 722,842
Derecognition of contingent consideration (5,199,806) 0
Gain on the change in fair value of CVR payout (267,130) 0
Issuance of common stock to employee 0 11,690
Derivative income (1,830) (65,468)
Changes in operating assets and liabilities:    
(Increase) in accounts receivable (8,183,810) (797,576)
(Increase) in inventory (345,452) (191,110)
(Increase) in prepaid expenses and other (1,611,681) (364,831)
(Increase) in other current assets (358,022) 0
(Decrease) in accounts payable and other (4,912,245) (191,331)
Increase in accrued liabilities 6,761,319 758,370
Increase in accrued compensation 271,560 250,912
(Decrease) in fixed payment arrangements (657,655) 0
Increase in interest payable 0 134,795
Net cash used in operating activities (20,609,198) (10,357,501)
Cash flows used in investing activities    
Deposit 0 2,888
Purchases of fixed assets 0 (59,848)
Contingent consideration payment (151,648) (408,917)
Cash received from acquisition 390,916 0
Purchase of assets (5,850,000) (500,000)
Net cash used in investing activities (5,610,732) (965,877)
Cash flows from financing activities    
Issuance of preferred, common stock and warrants 58,999,666 15,180,000
Issuance costs related to preferred, common stock and warrants (5,280,426) (1,479,963)
Warrant exercises 22,989,666 258,512
Preferred stock converted in common stock 92,880 0
Issuance of note payable 640,000 5,000,000
Net cash provided by financing activities 77,441,786 18,958,549
Net change in cash, restricted cash and cash equivalents 51,221,856 7,635,171
Cash, restricted cash and cash equivalents at beginning of period 11,294,227 7,112,527
Cash, restricted cash and cash equivalents at end of period 62,516,083 14,747,698
Supplemental disclosures of cash and non-cash investing and financing transactions    
Cash paid for interest 392,641 0
Fair value of right-to-use asset and related lease liability 354,929 0
Issuance of Series G preferred stock due to acquisition of the Cerecor portfolio of pediatrics therapeutics 5,559,914 0
Issuance of Series H preferred stock due to acquisition of the Innovus 12,805,263 0
Inventory payment included in accounts payable 460,416 0
Contingent consideration included in accounts payable 27,571 29,348
Fixed payment arrangements included in accounts payable 501,766 0
Exchange of convertible preferred stock into common stock 1,559 0
Return deductions received by Cerecor 2,000,000 0
Issuance of restricted stock 107 0
Cashless warrant exercises 792 0
Fair value of warrants issued to investors and underwriters 0 1,888,652
Issuance of preferred stock related to purchase of asset 0 519,600
Contingent consideration related to purchase of asset $ 0 $ 8,833,219